AMS Stock Analysis
AM
Avoid
Based on Eyestock quantitative analysis, AMS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly undervalued
American Shared Hospital Services engages in leasing radiosurgery and radiation therapy equipment to healthcare providers. The company is headquartered in San Francisco, California and currently employs 8 full-time employees. The firm is a provider of Gamma Knife radiosurgery equipment, a non-invasive treatment for malignant and benign brain tumors, vascular malformations, and trigeminal neuralgia (facial pain). The company can be an adjunct to conventional brain surgery, radiation therapy or chemotherapy. Typically, Gamma Knife patients resume their pre-surgical activities one or two days after treatment. The firm also offers proton therapy, and the IGRT, IMRT and MR/LINAC systems. The firm provides Gamma Knife units to approximately 12 medical centers in 11 states in the United States and two Gamma Knife units at stand-alone facilities in Lima, Peru and Guayaquil, Ecuador. The Company’s subsidiaries include American Shared Radiosurgery Services (ASRS), OR21, Inc. and MedLeader.com, Inc. (MedLeader).